7-Bromo-4-fluoro-1-benzothiophene-2-carboxylic acid | 1098607-72-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 7-Bromo-4-fluoro-1-benzothiophene-2-carboxylic acid
• CAS: 1098607-72-7
• 化学式: C₉H₄BrFO₂S
• 分子量: 275.098
• InChiKey: KGXGURYNQOMVOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-Bromo-4-fluoro-1-benzothiophene-2-carboxylic acid 在 四(三苯基膦)钯 、 硼烷四氢呋喃络合物 、 水 、 三溴化磷 、 sodium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 乙醚 、 乙醇 、 水 为溶剂， 反应 35.5h， 生成 3-{4-fluoro-2-[3-(trifluoromethyl)benzyl]-1-benzothien-7-yl}benzoic acid
  参考文献：
  名称：

  Discovery of the First Potent and Orally Available Agonist of the Orphan G-Protein-Coupled Receptor 52

  摘要：

  G-protein-coupled receptor 52 (GPR52) is an orphan Gs-coupled G-protein-coupled receptor. GPR52 inhibits dopamine D2 receptor signaling and activates dopamine D1/N-methyl-d-aspartate receptors via intracellular cAMP accumulation, and therefore, GPR52 agonists may have potential as a novel class of antipsychotics. A series of GPR52 agonists with a bicyclic core was designed to fix the conformation of the phenethyl ether moiety of compounds 2a and 2b. 3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide 7m showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties. Compound 7m significantly suppressed methamphetamine-induced hyperactivity in mice after oral administration of 3 mg/kg without disturbance of motor function.

  DOI：

  10.1021/jm5002919
• 作为产物：
  描述：

  ethyl 7-bromo-4-fluoro-1-benzothiophene-2-carboxylate 以 sodium hydroxide 、 乙醇 为溶剂， 生成 7-Bromo-4-fluoro-1-benzothiophene-2-carboxylic acid
  参考文献：
  名称：

  Pharmaceutical compounds

  摘要：

  这项发明涉及到式(I)的化合物，其中R1至R12，—W—V—，—X—Y—，m和n的值如权利要求1中定义的，它们的制备和用作药物。

  公开号：

  US20040122001A1

文献信息

• Pharmaceutical compounds
  申请人：——

  公开号：US20040122001A1

  公开（公告）日：2004-06-24

  This invention relates to compounds of formula (I) where R 1 to R 12 , —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals. 1

  这项发明涉及到式(I)的化合物，其中R1至R12，—W—V—，—X—Y—，m和n的值如权利要求1中定义的，它们的制备和用作药物。
• PHARMACEUTICAL COMPOUNDS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1345930A2

  公开（公告）日：2003-09-24
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2002050067A2

  公开（公告）日：2002-06-27

  This invention relates to compounds of formula (I) where R?1 to R12¿, -W-V-, -X-Y-, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.
• [EN] AMIDE COMPOUND<br/>[FR] COMPOSÉ AMIDE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010018874A1

  公开（公告）日：2010-02-18

  A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive / therapeutic agent for schizophrenia or the like. The compound is represented by the following formula (Ia): wherein A represents -CONR2- or -NR2CO-, R2 represents a hydrogen atom or the like, B represents a hydrogen atom or the like, a ring CyI represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B, a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like, a ring Cy3 represents a five- or six-membered ring which may have one or more substituents; X represents C1-2 alkylene or the like, m represents an integer of 0 to 2, and a ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.
• Discovery of the First Potent and Orally Available Agonist of the Orphan G-Protein-Coupled Receptor 52
  作者：Masaki Setoh、Naoki Ishii、Mitsunori Kono、Yuhei Miyanohana、Eri Shiraishi、Toshiya Harasawa、Hiroyuki Ota、Tomoyuki Odani、Naoyuki Kanzaki、Kazunobu Aoyama、Teruki Hamada、Masakuni Kori

  DOI：10.1021/jm5002919

  日期：2014.6.26

  G-protein-coupled receptor 52 (GPR52) is an orphan Gs-coupled G-protein-coupled receptor. GPR52 inhibits dopamine D2 receptor signaling and activates dopamine D1/N-methyl-d-aspartate receptors via intracellular cAMP accumulation, and therefore, GPR52 agonists may have potential as a novel class of antipsychotics. A series of GPR52 agonists with a bicyclic core was designed to fix the conformation of the phenethyl ether moiety of compounds 2a and 2b. 3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide 7m showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties. Compound 7m significantly suppressed methamphetamine-induced hyperactivity in mice after oral administration of 3 mg/kg without disturbance of motor function.